XML 35 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Significant Accounting Policies, Revenue Recognition (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2017
USD ($)
Feb. 28, 2017
USD ($)
Jul. 31, 2016
USD ($)
May 31, 2015
USD ($)
Dec. 31, 2012
USD ($)
Mar. 31, 2018
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Agreement
Jun. 30, 2015
USD ($)
Dec. 31, 2017
USD ($)
Revenue Recognition [Abstract]                      
Revenue           $ 144,419     $ 115,800    
Increase in revenue under new revenue guidance                 5,500    
Increase in revenue from amortization of milestone payments achieved under new revenue guidance                 10,300    
Decrease in revenue from amortization of payments using input method under new revenue guidance                 $ (3,800)    
Number of agreements with Novartis | Agreement                 2    
Period of time after billing when payment is received           3 months          
Deferred Revenue [Abstract]                      
Revenue recognized           $ 34,900     $ 26,700    
Current portion of deferred revenue $ 125,336         120,127         $ 125,336
Long-term portion of deferred revenue 108,026         85,446         108,026
Total 233,362                   233,362
Increase in deferred revenue                 54,200    
Biogen [Member]                      
Deferred Revenue [Abstract]                      
Increase in deferred revenue           24,200          
AstraZeneca [Member]                      
Deferred Revenue [Abstract]                      
Increase in deferred revenue           15,900          
Novartis [Member]                      
Deferred Revenue [Abstract]                      
Increase in deferred revenue           11,800          
Other Partners [Member]                      
Deferred Revenue [Abstract]                      
Increase in deferred revenue           2,300          
IONIS-DMPK [Member]                      
Revenue Recognition [Abstract]                      
Additional revenue recognized related to changes in estimates                 8,200    
SMA Collaboration with Biogen [Member]                      
Revenue Recognition [Abstract]                      
Upfront payment received 25,000                    
Neurology [Member]                      
Revenue Recognition [Abstract]                      
Additional revenue recognized related to changes in estimates                 500    
Upfront payment received         $ 30,000            
Milestone payment earned and amortized over period of performance             $ 10,000        
SPINRAZA [Member]                      
Revenue Recognition [Abstract]                      
Milestone payment earned and recognized               $ 50,000      
Bayer [Member]                      
Revenue Recognition [Abstract]                      
Upfront payment received       $ 100,000           $ 100,000  
Bayer [Member]                      
Revenue Recognition [Abstract]                      
Upfront payment received   $ 75,000                  
Novartis [Member]                      
Deferred Revenue [Abstract]                      
Total 70,700         56,700         70,700
Commercial Revenue [Member]                      
Revenue Recognition [Abstract]                      
Revenue           42,023     7,801    
SPINRAZA Royalties [Member]                      
Revenue Recognition [Abstract]                      
Revenue           41,081     5,211    
Licensing and Other Royalty Revenue [Member]                      
Revenue Recognition [Abstract]                      
Revenue           942     2,590    
Licensing and Other Royalty Revenue [Member] | SPINRAZA [Member]                      
Revenue Recognition [Abstract]                      
Revenue     $ 75,000                
Research and Development Under Collaborative Agreements [Member]                      
Revenue Recognition [Abstract]                      
Revenue           102,396     107,999    
Research and Development Under Collaborative Agreements [Member] | SPINRAZA [Member]                      
Revenue Recognition [Abstract]                      
Revenue                     90,000
Research and Development Under Collaborative Agreements [Member] | Novartis [Member]                      
Revenue Recognition [Abstract]                      
Revenue           $ 17,100     6,100    
New Revenue Recognition Accounting Standard [Member]                      
Revenue Recognition [Abstract]                      
Cumulative effect of adoption on retained earnings (53,600)                   (53,600)
New Revenue Recognition Accounting Standard [Member] | As Previously Reported Under Topic 605 [Member]                      
Revenue Recognition [Abstract]                      
Revenue                 110,304    
Deferred Revenue [Abstract]                      
Current portion of deferred revenue 106,465                   106,465
Long-term portion of deferred revenue 72,708                   72,708
Total 179,173                   179,173
New Revenue Recognition Accounting Standard [Member] | As Previously Reported Under Topic 605 [Member] | Commercial Revenue [Member]                      
Revenue Recognition [Abstract]                      
Revenue                 8,758    
New Revenue Recognition Accounting Standard [Member] | As Previously Reported Under Topic 605 [Member] | SPINRAZA Royalties [Member]                      
Revenue Recognition [Abstract]                      
Revenue                 5,211    
New Revenue Recognition Accounting Standard [Member] | As Previously Reported Under Topic 605 [Member] | Licensing and Other Royalty Revenue [Member]                      
Revenue Recognition [Abstract]                      
Revenue                 3,547    
New Revenue Recognition Accounting Standard [Member] | As Previously Reported Under Topic 605 [Member] | Research and Development Under Collaborative Agreements [Member]                      
Revenue Recognition [Abstract]                      
Revenue                 101,546    
New Revenue Recognition Accounting Standard [Member] | Topic 606 Adjustment [Member]                      
Revenue Recognition [Abstract]                      
Revenue                 5,496    
Deferred Revenue [Abstract]                      
Current portion of deferred revenue 18,871                   18,871
Long-term portion of deferred revenue 35,318                   35,318
Total $ 54,189                   $ 54,189
New Revenue Recognition Accounting Standard [Member] | Topic 606 Adjustment [Member] | Commercial Revenue [Member]                      
Revenue Recognition [Abstract]                      
Revenue                 (957)    
New Revenue Recognition Accounting Standard [Member] | Topic 606 Adjustment [Member] | SPINRAZA Royalties [Member]                      
Revenue Recognition [Abstract]                      
Revenue                 0    
New Revenue Recognition Accounting Standard [Member] | Topic 606 Adjustment [Member] | Licensing and Other Royalty Revenue [Member]                      
Revenue Recognition [Abstract]                      
Revenue                 (957)    
New Revenue Recognition Accounting Standard [Member] | Topic 606 Adjustment [Member] | Research and Development Under Collaborative Agreements [Member]                      
Revenue Recognition [Abstract]                      
Revenue                 $ 6,453